Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Down 97.8% in April

Posted by Geri Gentry on May 11th, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 16 shares, a decline of 97.8% from the April 15th total of 719 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 3,446 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

AAPG has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price for the company. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Finally, BTIG Research reissued a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $46.67.

Get Our Latest Report on AAPG

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AAPG. XY Capital Ltd increased its stake in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the period. UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Finally, ABC Arbitrage SA bought a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $204,000.

Ascentage Pharma Group International Stock Up 0.7%

Shares of Ascentage Pharma Group International stock traded up $0.16 on Monday, hitting $21.66. The stock had a trading volume of 1,455 shares, compared to its average volume of 2,900. The stock has a 50 day moving average of $24.01 and a 200 day moving average of $27.03. Ascentage Pharma Group International has a twelve month low of $19.11 and a twelve month high of $48.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million during the quarter. As a group, equities research analysts forecast that Ascentage Pharma Group International will post -1.09 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.